Compare Axon Enterprise Inc (AXON) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs Gilead Sciences, Inc. — how do they compare? Axon Enterprise Inc trades at $544.84 (market cap $44.11B), while Gilead Sciences, Inc. trades at $132.1 (market cap $161.45B). The key difference: Gilead Sciences, Inc. is far larger — about 3.7× Axon Enterprise Inc's market cap, and Gilead Sciences, Inc. pays a 2.52% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | GILD | |
|---|---|---|
Market Cap | $44.11B | $161.45B |
Sector | Technology | Health |
52-Week High | $870.97 | $155.80 |
52-Week Low | $345.94 | $108.22 |
Enterprise Value | $45.20B | $175.98B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $547.03, down 3.32% on the day, with strong analyst support (81% buy ratings) and a consensus price target of $648.67. The stock shows bullish technical signals with support at $539 and resistance at $553. Recent earnings have been mixed with Q3 2025 missing estimates but Q4 2025 and Q1 2026 beating expectations. Revenue growth remains solid with 2026 projections at $3.0B and net profit margin improving to 6.9%.
Axon presents growth potential driven by strong demand for connected devices and software services, though elevated valuation ratios (P/E 220.67) pose risk. Positive sentiment stems from recent upgrades and institutional interest, including notable insider buying. Key risks include execution challenges and competitive pressures in the law enforcement technology sector.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
